This acquisition underlines Pfizer’s fresh push into the booming weight-loss drug market, an area showing rapid growth as obesity rates climb worldwide. Pfizer eyes Metsera obesity breakthroughCopy link to sectionThe deal offers Metsera shareholders $47.50 per share in cash, with an additional $22.50 per share payable if certain performance targets are hit. Pfizer’s acquisition would be a sharp turnaround after it halted its own oral GLP-1 drug development earlier this year due to safety issues. Obesity drug race heats upCopy link to sectionPfizer’s move is a clear sign of how hot the obesity drug market has become, dominated until now by giants like Novo Nordisk and Eli Lilly. The acquisition is poised to intensify competition and could spark more deals and technological advances, as companies race to capture a share of the lucrative, fast-evolving obesity drug market.